Shire (NASDAQ:SHPG) Stock Rating Upgraded by Liberum Capital

Shire (NASDAQ:SHPG) was upgraded by Liberum Capital from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday, November 14th.

Other analysts also recently issued research reports about the stock. Cantor Fitzgerald restated a “buy” rating and set a $222.00 price target on shares of Shire in a report on Monday, August 21st. BTIG Research restated a “buy” rating and set a $242.00 price target on shares of Shire in a report on Monday, July 17th. Royal Bank Of Canada set a $213.00 price target on shares of Shire and gave the stock a “buy” rating in a report on Friday, August 4th. Stifel Nicolaus restated a “buy” rating and set a $245.00 price target on shares of Shire in a report on Sunday, October 8th. Finally, FBR & Co initiated coverage on shares of Shire in a report on Thursday, October 19th. They issued a “buy” rating and a $201.00 target price for the company. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the company’s stock. Shire currently has an average rating of “Hold” and an average target price of $212.18.

Shares of Shire (SHPG) traded down $0.50 on Tuesday, reaching $148.25. The company’s stock had a trading volume of 649,020 shares, compared to its average volume of 1,072,997. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.98 and a quick ratio of 0.52. Shire has a 12 month low of $137.17 and a 12 month high of $192.15. The firm has a market cap of $44,538.30, a P/E ratio of 10.20, a P/E/G ratio of 0.82 and a beta of 1.60.

Shire (NASDAQ:SHPG) last issued its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.64 by $0.17. The firm had revenue of $3.70 billion for the quarter. Shire had a net margin of 10.95% and a return on equity of 14.41%. The company’s quarterly revenue was up 7.1% compared to the same quarter last year. During the same period in the prior year, the business posted $3.17 earnings per share. analysts predict that Shire will post 15 earnings per share for the current fiscal year.

Institutional investors have recently modified their holdings of the company. Harding Loevner LP boosted its holdings in Shire by 18,894.4% during the third quarter. Harding Loevner LP now owns 127,537,052 shares of the biopharmaceutical company’s stock worth $20,354,000 after buying an additional 126,865,607 shares in the last quarter. Maverick Capital Ltd. boosted its holdings in Shire by 19.9% during the second quarter. Maverick Capital Ltd. now owns 1,942,087 shares of the biopharmaceutical company’s stock worth $320,969,000 after buying an additional 322,610 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in Shire by 35.3% during the third quarter. Janus Henderson Group PLC now owns 1,740,973 shares of the biopharmaceutical company’s stock worth $266,613,000 after buying an additional 454,092 shares in the last quarter. Glenview Capital Management LLC boosted its holdings in Shire by 69.7% during the second quarter. Glenview Capital Management LLC now owns 1,722,977 shares of the biopharmaceutical company’s stock worth $284,756,000 after buying an additional 707,500 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its holdings in Shire by 6.4% during the third quarter. Ameriprise Financial Inc. now owns 1,606,342 shares of the biopharmaceutical company’s stock worth $245,997,000 after buying an additional 96,115 shares in the last quarter. Institutional investors and hedge funds own 62.41% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was first published by BBNS and is the property of of BBNS. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://baseballnewssource.com/markets/shire-plc-shpg-upgraded-to-buy-by-liberum-capital/1783075.html.

About Shire

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.